Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Stifel 2025 Virtual Ophthalmology Forum. The company's management will engage in a fireside chat on Tuesday, May 27, 2025, at 9:00 a.m. ET. Investors and interested parties can access the live and archived webcast through the Events and Presentations section of Clearside's website. The webcast recording will remain available for three months after the event.
Clearside Biomedical (NASDAQ: CLSD), un'azienda biofarmaceutica specializzata nello sviluppo di terapie per la parte posteriore dell'occhio tramite lo spazio suprachoroidale (SCS®), parteciperà al Stifel 2025 Virtual Ophthalmology Forum. Il management dell'azienda sarà protagonista di una conversazione informale martedì 27 maggio 2025 alle ore 9:00 ET. Investitori e interessati potranno seguire la diretta e la registrazione dell'evento nella sezione Eventi e Presentazioni del sito web di Clearside. La registrazione sarà disponibile per tre mesi dopo l'evento.
Clearside Biomedical (NASDAQ: CLSD), una compañía biofarmacéutica enfocada en ofrecer terapias para la parte posterior del ojo a través del espacio supracoroideo (SCS®), participará en el Stifel 2025 Virtual Ophthalmology Forum. La dirección de la empresa participará en una charla informal el martes 27 de mayo de 2025 a las 9:00 a.m. ET. Inversionistas e interesados podrán acceder a la transmisión en vivo y a la grabación a través de la sección de Eventos y Presentaciones en la página web de Clearside. La grabación estará disponible durante tres meses después del evento.
Clearside Biomedical (NASDAQ: CLSD)는 후안부 눈 치료를 위해 초공막 공간(SCS®)을 통한 치료법 개발에 주력하는 바이오제약 회사로, Stifel 2025 Virtual Ophthalmology Forum에 참여할 예정입니다. 회사 경영진은 2025년 5월 27일 화요일 오전 9시(동부시간)에 진행되는 대화형 토론에 참여합니다. 투자자 및 관심 있는 분들은 Clearside 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 생중계와 녹화 영상을 시청할 수 있습니다. 녹화 영상은 행사 후 3개월간 제공됩니다.
Clearside Biomedical (NASDAQ : CLSD), une société biopharmaceutique spécialisée dans la fourniture de thérapies pour la partie postérieure de l'œil via l'espace suprachoroïdien (SCS®), participera au Stifel 2025 Virtual Ophthalmology Forum. La direction de l'entreprise prendra part à une discussion informelle le mardi 27 mai 2025 à 9h00 ET. Les investisseurs et les personnes intéressées pourront accéder au webcast en direct ainsi qu'à son enregistrement via la section Événements et Présentations du site web de Clearside. L'enregistrement restera disponible pendant trois mois après l'événement.
Clearside Biomedical (NASDAQ: CLSD), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für den hinteren Teil des Auges über den suprachoroidalen Raum (SCS®) spezialisiert hat, wird am Stifel 2025 Virtual Ophthalmology Forum teilnehmen. Das Management des Unternehmens wird am Dienstag, den 27. Mai 2025, um 9:00 Uhr ET an einem Gespräch teilnehmen. Investoren und Interessierte können den Live-Stream und die Aufzeichnung über den Bereich Veranstaltungen und Präsentationen auf der Website von Clearside abrufen. Die Aufzeichnung wird drei Monate nach der Veranstaltung verfügbar sein.
- None.
- None.
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical (CLSD) presenting at the Stifel 2025 Virtual Ophthalmology Forum?
How can investors access Clearside Biomedical's (CLSD) presentation at the Stifel Forum?
How long will Clearside Biomedical's (CLSD) Stifel Forum presentation be available for viewing?
What is Clearside Biomedical's (CLSD) main focus as a company?
